New Drug-eluting Stent Concepts

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Mar 3

PMID 20195268

Citations 31

Authors

Rainer Wessely

Affiliations

Soon will be listed here.

Abstract

Drug-eluting stents (DES) have revolutionized interventional cardiology. The first bare-metal stents successfully prevented abrupt artery closure and reduced the likelihood of clinical restenosis compared with balloon angioplasty. They were, however, limited by the frequent occurrence of restenosis owing to smooth muscle proliferation, and resultant neointimal hyperplasia and target lesion revascularization. By coating stents with drugs that target smooth muscle cell proliferation, it has been possible to considerably attenuate in-stent restenosis. This innovative technology still has shortcomings, however, and novel approaches are needed to improve the safety and efficacy of DES. The main components that determine the performance of a stent are the stent backbone, active drug, polymer and delivery system, and each of these factors need to be examined to optimize DES platforms. Improvements include the use of new coating technologies, bioabsorbable stents, non-drug-based stent coatings, and tailored lesion therapy. Efforts to develop this technology further will greatly enhance the outcome for patients with coronary artery disease.

Citing Articles

Long-Term Clinical Outcomes of Polymer-Free Sirolimus-Eluting Stent and Polymer-Coated Sirolimus-Eluting Stent in Patients with Type 2 Diabetes.

Yang O, Teng Y, Zhang R, Qu J Int J Nanomedicine. 2024; 19:11689-11700.

PMID: 39553456 PMC: 11566208. DOI: 10.2147/IJN.S482608.

Tissue factor targeting peptide enhances nanoparticle binding and delivery of a synthetic specialized pro-resolving lipid mediator to injured arteries.

Levy E, Kim A, Werlin E, Chen M, Sansbury B, Spite M JVS Vasc Sci. 2023; 4:100126.

PMID: 38045567 PMC: 10692706. DOI: 10.1016/j.jvssci.2023.100126.

Liquid Metal-Based Flexible Bioelectrodes for Management of In-Stent-Restenosis: Potential Application.

Zhang X, Li L, Deng Z Biosensors (Basel). 2023; 13(8).

PMID: 37622881 PMC: 10452354. DOI: 10.3390/bios13080795.

Cardiovascular effects of immunosuppression agents.

Elezaby A, Dexheimer R, Sallam K Front Cardiovasc Med. 2022; 9:981838.

PMID: 36211586 PMC: 9534182. DOI: 10.3389/fcvm.2022.981838.

3D-printed Bioresorbable Stent Coated with Dipyridamole-Loaded Nanofiber for Restenosis Prevention and Endothelialization.

Wang C, Yang Y, Ji J, Fang Y, Ouyang L, Zhang L Int J Bioprint. 2022; 8(2):543.

PMID: 35669322 PMC: 9159485. DOI: 10.18063/ijb.v8i2.543.

References

Downward J . RNA interference. BMJ. 2004; 328(7450):1245-8. PMC: 416605. DOI: 10.1136/bmj.328.7450.1245. View

Udipi K, Melder R, Chen M, Cheng P, Hezi-Yamit A, Sullivan C . The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention. 2009; 3(1):137-9. View

Adriaenssens T, Mehilli J, Wessely R, Ndrepepa G, Seyfarth M, Wieczorek A . Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol. 2007; 49(12):1265-71. DOI: 10.1016/j.jacc.2007.02.021. View

Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S . Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005; 25(4):748-53. DOI: 10.1161/01.ATV.0000157579.52566.ee. View

Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S . Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102(4):399-404. DOI: 10.1161/01.cir.102.4.399. View

Serruys P, Ormiston J, Sianos G, Sousa J, Grube E, den Heijer P . Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol. 2004; 44(7):1363-7. DOI: 10.1016/j.jacc.2004.03.084. View

Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, de Groot P . Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation. 2001; 104(8):928-33. DOI: 10.1161/hc3401.093146. View

Wessely R, Kastrati A, Schomig A . Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005; 143(5):392-4. DOI: 10.7326/0003-4819-143-5-200509060-00119. View

Lewis A, Willis S, Small S, Hunt S, OByrne V, Stratford P . Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo. Biomed Mater Eng. 2004; 14(4):355-70. View

10.

Weisz G, Leon M, Holmes Jr D, Kereiakes D, Popma J, Teirstein P . Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009; 53(17):1488-97. DOI: 10.1016/j.jacc.2009.01.050. View

11.

Park D, Hong M, Mintz G, Lee C, Song J, Han K . Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study. J Am Coll Cardiol. 2006; 48(12):2432-9. DOI: 10.1016/j.jacc.2006.08.033. View

12.

Costa Jr J, Abizaid A, Costa R, Feres F, Tanajura L, Abizaid A . 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc Interv. 2009; 2(5):422-7. DOI: 10.1016/j.jcin.2009.02.009. View

13.

Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S . Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv. 2009; 2(4):277-83. DOI: 10.1016/j.jcin.2008.08.023. View

14.

Karjalainen P, Ylitalo A, Niemela M, Kervinen K, Makikallio T, Pietili M . Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention. 2008; 4(2):234-41. DOI: 10.4244/eijv4i2a42. View

15.

Sigwart U . Drug-eluting stents are safe and effective: right or wrong?. J Am Coll Cardiol. 2006; 47(7):1361-2. DOI: 10.1016/j.jacc.2006.02.001. View

16.

Abizaid A, Albertal M, Costa M, Abizaid A, Staico R, Feres F . First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol. 2004; 43(6):1118-21. DOI: 10.1016/j.jacc.2004.01.023. View

17.

Wessely R, Schomig A, Kastrati A . Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006; 47(4):708-14. DOI: 10.1016/j.jacc.2005.09.047. View

18.

Ferrero V, Ribichini F, Rognoni A, Marino P, Brunelleschi S, Vassanelli C . Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study). Am J Cardiol. 2007; 99(8):1082-6. DOI: 10.1016/j.amjcard.2006.11.064. View

19.

Verheye S, Agostoni P, Dawkins K, Dens J, Rutsch W, Carrie D . The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. JACC Cardiovasc Interv. 2009; 2(3):205-14. DOI: 10.1016/j.jcin.2008.12.011. View

20.

Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A . Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv. 2004; 64(1):85-90. DOI: 10.1002/ccd.20213. View